Diphenhydramine toxicity label warning for oral, topical products proposed by FDA.
This article was originally published in The Tan Sheet
Executive Summary
DIPHENHYDRAMINE TOXICITY LABEL WARNING PROPOSED BY FDA that would advise consumers not to use topical products containing the ingredient on chicken pox, poison ivy, sunburn, large areas of the body, blistered or oozing skin, more often than directed or with any other diphenhydramine-containing product, including those taken orally. FDA published the notice of proposed rulemaking in the Aug. 29 Federal Register. Written comments on the proposal are due by Nov. 28. A final rule would go into effect one year after publication.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning